Company news

Sarepta Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Sarepta Therapeutics and GenEdit Share Progress on Research Collaboration and Announce Agreement to Develop Gene Editing Therapeutics for Neuromuscular Diseases

January 31, 2022

Sarepta Therapeutics’ Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for the Treatment of Duchenne Muscular Dystrophy

January 9, 2022

Sarepta Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 5, 2022

Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development

November 16, 2021

Sarepta Therapeutics Appoints Stephen L. Mayo, Ph.D., to its Board of Directors

November 16, 2021

Sarepta Therapeutics Announces Third Quarter 2021 Financial Results and Recent Corporate Developments

November 2, 2021

Sarepta Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Developments on November 3, 2021

October 26, 2021

Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock

October 12, 2021

Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock

October 11, 2021

Sarepta Therapeutics Announces Preliminary Financial Results for the Third Quar-ter Ended September 30, 2021

October 11, 2021

Sarepta Therapeutics’ SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne

October 10, 2021

Sarepta Therapeutics Opens Genetic Therapies Center of Excellence in Columbus, Ohio

October 3, 2021

Sarepta Therapeutics Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001, a Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

October 3, 2021

Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA

September 26, 2021

Sarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual Congress

September 13, 2021

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program

September 6, 2021

Sarepta Therapeutics Executes Licensing Agreement for Gene Therapy Program from Nationwide Children’s Hospital to Treat Limb-Girdle Muscular Dystrophy Type 2A

August 3, 2021

Sarepta Therapeutics Announces Second Quarter 2021 Financial Results and Recent Corporate Developments

August 3, 2021

Sarepta Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Developments on August 4, 2021

July 27, 2021

Sarepta Therapeutics’ Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001, Demonstrates Robust Expression and Consistent Safety Profile Using Sarepta’s Commercial Process Material

May 17, 2021

Sarepta Therapeutics to Share Expression and Safety Results from Study 103 (ENDEAVOR) Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

May 16, 2021

Sarepta Therapeutics Announces First Quarter 2021 Financial Results and Recent Corporate Developments

May 4, 2021

Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

May 2, 2021

Sarepta Therapeutics to Share Clinical Update for 30 mg/kg arm of MOMENTUM Study for SRP-5051, Its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy

April 29, 2021

Sarepta Therapeutics to Announce First Quarter 2021 Financial Results and Recent Corporate Developments on May 5, 2021

April 27, 2021

Sarepta Recommends Stockholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation

April 25, 2021

Sarepta Therapeutics Announces Fourth Year of Route 79, The Duchenne Scholarship Program

March 22, 2021

Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration

March 17, 2021

Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference

March 14, 2021

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments

February 28, 2021

Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45

February 24, 2021

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments on March 1, 2021

February 21, 2021

Sarepta Therapeutics Announces Winners of the “Rare Lessons” Lesson Planning Competition

February 3, 2021

Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics

January 12, 2021

Sarepta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 7, 2021

Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

January 6, 2021

Sarepta Therapeutics Announces Executive Management Changes

December 13, 2020

Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

December 6, 2020

Sarepta Therapeutics to Share Clinical Update for SRP-5051, its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy

December 3, 2020

Sarepta Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference

November 24, 2020

Sarepta Therapeutics Named One of The Boston Globe’s Top Places to Work 2020

November 19, 2020

Sarepta Therapeutics to Commence Dosing of the Next Study with Commercial Process Material for the SRP-9001 Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy

November 4, 2020

Sarepta Therapeutics Announces Third Quarter 2020 Financial Results and Recent Corporate Developments

November 4, 2020

Sarepta Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference

November 1, 2020

Sarepta Therapeutics to Announce Third Quarter 2020 Financial Results and Recent Corporate Developments on November 5, 2020

October 28, 2020

Sarepta Therapeutics Reports Sustained Functional Improvement Two Years After Treatment with SRP-9001, its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy

September 27, 2020

Sarepta Therapeutics Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Functional Improvements 18-months After Administration

September 27, 2020

Long-term functional data from Sarepta Therapeutics’ Most Advanced Gene Therapy Programs to be Presented at Upcoming Annual Congress of the World Muscle Society

September 13, 2020

Sarepta Therapeutics Provides Program Update for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

September 8, 2020

Sarepta Therapeutics Announces FDA Acceptance of Casimersen (SRP-4045) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45

August 24, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 37 decks. Every deck is listed under its year.